#China #Chengdu #SBTi #climate action #HitGen

HitGen's Commitment to Science-Based Targets: Paving the Path for Sustainability

On December 15, 2025, HitGen Inc., a leading biopharmaceutical company based in Chengdu, China (SSE: 688222.SH), took a significant step towards sustainability by officially submitting its commitment letter to the Science Based Targets initiative (SBTi). This initiative is designed to aid companies in establishing robust, science-based emission reduction targets that align with the goals outlined in the Paris Agreement.

The Commitment to Act

HitGen's commitment entails the establishment of near-term, science-based targets within the next two years. These targets will be developed in accordance with the rigorous standards set by the SBTi, which aims to guide organizations toward significant reductions in greenhouse gas emissions across their entire value chain. The ultimate goal of this initiative is to contribute to achieving the 1.5°C temperature limitation set by the Paris climate accords.

In recent years, climate change has emerged as one of the most pressing global challenges. The impacts are far-reaching, affecting health outcomes, economic stability, and social structures. Recognizing this urgency, HitGen has committed itself to implement a series of emission reduction measures designed to address this challenge head-on.

A Corporate Responsibility

Dr. Jin Li, Chairman and CEO of HitGen, expressed pride in the company's commitment, emphasizing the importance of corporate social responsibility. “By joining this global coalition of corporate climate leaders, we are taking tangible action to foster a healthier planet for future generations,” he stated. “This commitment aligns seamlessly with our mission to enhance human health through innovative science.”

The pledge not only underlines HitGen's resolve to integrate sustainable practices into its operations but also signifies a broader trend among companies worldwide. Over 10,000 organizations across more than 100 countries have already made similar commitments through the SBTi, highlighting the collective movement toward combating climate change.

Looking Forward: The Path of Decarbonization

HitGen's strategy goes beyond merely reducing its own emissions; it aims to influence and inspire a transition towards greener practices throughout its entire industrial chain. The integration of science-based decarbonization pathways is expected to minimize the environmental impact of HitGen’s operations while promoting sustainable practices among its partners and stakeholders.

Moreover, the commitment to reducing emissions is particularly relevant in the biopharmaceutical sector, where production processes can be resource-intensive. By redirecting focus towards sustainability, HitGen promises not only to innovate in health solutions but also to lead by example in environmental stewardship.

A Call to Action for All Businesses

As HitGen embarks on this ambitious journey, its commitment serves as an important reminder of the role businesses must play in addressing climate change. The pathway towards sustainability can be challenging, but with the framework provided by initiatives like the SBTi, organizations can set achievable targets that contribute significantly to global climate goals.

In conclusion, HitGen’s submission of its commitment letter to the SBTi marks a critical milestone in its sustainability endeavors. It serves as an emblem of the biopharmaceutical sector’s capacity to lead the charge in climate action, ultimately aiming for a healthier planet and improved public health outcomes. As more companies join this movement, the ripple effects could reshape entire industries and pave the way for a sustainable future.

• ---

Through this initiative, HitGen not only enhances its corporate responsibility but also positions itself as a leader in the fight against climate change, proving that innovation in health should go hand-in-hand with care for our planet.